Skip to Main Content

Dr. Charles J. Dimitroff has been studying the nature of lectin – carbohydrate interactions and their impact on inflammation and cancer for nearly three decades. He has expertise in glycobiology studies relating to tumor biology and adaptive immunity. He is qualified to perform pre-clinical research investigating how glycome-related molecules contribute to the pathogenesis of inflammation and cancer. His lab conducts both in vitro and in vivo experiments designed to characterize the identity and function of lectins and their carbohydrate-binding ligands on leukocytes and cancer cells.

 Dimitroff's experimental systems include the use of:

  • Carbohydrate inhibitors
  • MALDI-TOF-TOF MS/MS
  • "Homegrown" selectin/ galectin-human Fc chimeras and glycosyltransferase mutant cell lines/mice as glycobiological tools to identify and characterize selectin/galectin ligands functioning in inflammation, tumorigenesis, metastasis, tumor immune evasion, and lymphomagenesis
  • Native human tissues/cells as sources to isolate the relevant immune/cancer cells.

The Dimitroff lab is designed to train high school, undergraduate, graduate students, and post-doctoral fellows with an emphasis on building academic metrics and career advancement.

Charles J. Dimitroff, Ph.D., is a professor in the Department of Translational Medicine. He also serves as the director of the Translational Glycobiology Institute at FIU. His lab is located on the 4th floor of Academic Health Center 5. 

A laboratory focusing on the glyco-pathological basis of immunity, inflammation, and cancer.